Effectiveness of subcutaneous growth hormone in HIV-1 patients with moderate to severe facial lipoatrophy.

What Was Tested

This clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

To evaluate effect of recombinant human growth hormone (rhGH) among HIV-infected adults with moderate to severe facial lipoatrophy as a side effect of long-term antiretroviral treatment.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a single-blind, open-label and pilot study.

Only one side, usually the participants, was kept unaware of whether Exogenous HGH, sermorelin & older GHRPs (why they're passed over) was given.

Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the participants and staff both knew the treatment.

It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.

Facial lipoatrophy was evaluated by computed tomography at months 0, 3, 6 and 12.

What Was Measured

The subject headings attached to it are Analysis of Variance, Antiretroviral Therapy, Highly Active, Esthetics, Growth Hormone, HIV-Associated Lipodystrophy Syndrome, Pilot Projects and Probability.

What This Means in Plain Language

The paper is a single-blind, open-label and pilot study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2007 (Internal medicine (Tokyo, Japan)), a journal based in Japan.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.